We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Eurofins Technologies

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Jun 2020 - 09 Jun 2020
Virtual Venue
08 Jun 2020 - 11 Jun 2020
Virtual Venue

Pulmonary Biomarker Surfactant Protein-B Is Used for Diagnosis

By LabMedica International staff writers
Posted on 10 Dec 2008
Print article
Roche Diagnostics (Rotkreuz, Switzerland) and an Australian Biotech company, Southern Medical Diagnostics (SMD; Walkerville, Australia) signed licensing agreements on diagnostic applications of Surfactant Protein-B.

According to the agreements, Roche will have semi-exclusive worldwide rights for diagnostic applications of Surfactant Protein-B (SP-B) in lung disorders; SMD will have worldwide rights to key test-components developed by Roche, which SMD may exclusively use for SP-B applications.

A lung-specific protein and a key functional component of the alveolus, SP-B is present at very low concentrations in the serum of healthy people. It is released into the blood stream as a result of lung injury and is significantly increased in primary and secondary lung disorders affecting mainly the lung parenchyma. This includes the alveolocapillary system, such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and heart failure. Changes of lung disorders can be monitored by measuring levels of SP-B in the blood.

Together with B-type natriuretic peptide (BNP or NT-proBNP) tests, SP-B helps to discriminate between cardiac and non-cardiac causes of dyspnea.

"Roche Diagnostics believes that tests for Surfactant Protein-B will be very valuable in the diagnosis, differential diagnosis, and monitoring of patients with primary and secondary pulmonary disorders," said Dirk Ehlers, head of Roche Professional Diagnostics." He added, "The SP-B assay will allow earlier recognition of cardio-pulmonary conditions and thereby prepare the basis for improved treatment in the future."

Roche is one of the world's leading healthcare groups in the fields of diagnostics and pharmaceutics. The company is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.

Southern Medical Diagnostics Pty Ltd. is a private Australian company specializing in the development and out-licensing of novel diagnostic technologies.

Related Links:
Roche Diagnostics
Southern Medical Diagnostics


Print article

Channels

Microbiology

view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.